Please login to the form below

Not currently logged in
Email:
Password:

Alzheimer's disease

This page shows the latest Alzheimer's disease news and features for those working in and with pharma, biotech and healthcare.

First trial of a vaccine against Alzheimers launches

First trial of a vaccine against Alzheimer’s launches

For some time, researchers have looked to the brain's immune system as a key factor in the development of Alzheimer’s disease. ... migrate to the brain and trigger the clearance of beta amyloid plaque, one of the hallmarks of Alzheimer’s disease.

Latest news

More from news
Approximately 90 fully matching, plus 337 partially matching documents found.

Latest Intelligence

  • Alzheimer’s disease: the search for a cure Alzheimers disease: the search for a cure

    We need to fast-track new treatments. As of last year, there are over 100 treatments in clinical trials for Alzheimer’s disease. ... crucial support cells in the brain that normally help brain cells to function properly, but that can change and

  • Alzheimer’s: the search for a cure Alzheimers: the search for a cure

    By Peter Schueler. This year’s 14th annual Clinical Trials on Alzheimer’s Disease (CTAD) conference — entitled: ‘A New Hope for 2022?’ — will be held in Boston in November. ... Despite their limitations, available outcome scales, such as the

  • Alzheimer’s: the search for a cure Alzheimers: the search for a cure

    reduction in tauopathy,” said Paul Aisen, director of the Alzheimer’s Therapeutic Research Institute, at the Clinical Trials on Alzheimer’s Disease meeting where Biogen presented its data. ... Canaccord Genuity analysts forecast peak sales of

  • Great expectations: the urgent need for common purpose in Alzheimer’s disease Great expectations: the urgent need for common purpose in Alzheimers disease

    By Andrew Harrison. A few years ago, when communicating the phase 3 data of a major trial in Alzheimer’s disease (AD), our prime goal was focused on accuracy of reporting ... Most of us will have experience of family or friends with Alzheimer’s or

  • Can protein degraders unlock ‘undruggable’ drug targets? Can protein degraders unlock ‘undruggable’ drug targets?

    Now, interest is growing in a largely-untapped approach to targeting disease-associated proteins, particularly those that for many years have been considered ‘undruggable’. ... C4 also has a collaboration in place with Biogen focusing on neurological

More from intelligence
Approximately 6 fully matching, plus 30 partially matching documents found.

Latest appointments

  • J&J’s clinical research neuroscience director joins MedAvante J&J’s clinical research neuroscience director joins MedAvante

    Prior to this, he was medical director, global medical affairs for Janssen's Alzheimer's disease immunotherapy unit from June 2011 to May 2013. ... He also brings extensive experience in psychiatry, neurology and dermatology, making him an ideal addition

  • Asceneuron appoints chief medical officer Asceneuron appoints chief medical officer

    Alzheimer's disease. ... His outstanding track record and expertise in neurodegenerative disease are crucial as we are about to progress our first highly brain penetrant and orally bioavailable tau modifier into the clinic for

  • Pfizer appoints chief scientific officer Pfizer appoints chief scientific officer

    Having first joined Harvard in 1989, Dr Isacson's work in neurogenerative disorders, particularly for Parkinson's disease, has become internationally renowned with his laboratory now one of the leading academic ... s disease, where we are working to

  • Chase adds former Allergan execs to leadership team Chase adds former Allergan execs to leadership team

    With its robust intellectual property, pharmaceutical assets and elegant development strategy, Chase has the opportunity to profoundly reshape the approach to the symptomatic treatment of Alzheimer's disease. ... disease.”. 20th June 2016.

  • Eisai recruits Pfizer and Sanofi execs to neurology group Eisai recruits Pfizer and Sanofi execs to neurology group

    Eisai has also appointed Beyhan Zaim to its US Neurology Business Group as VP, commercial development and Alzheimer's Disease global lead. ... As global lead for Alzheimer's Disease she will also be tasked with developing strategies and heading internal

More from appointments
Approximately 0 fully matching, plus 18 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 2 fully matching, plus 17 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Impetus Digital

Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...